Compare Moody's Corporation (MCO) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs Tilray Brands Inc — how do they compare? Moody's Corporation trades at $461.84 (market cap $79.44B), while Tilray Brands Inc trades at $3.44 (market cap $530.54M). The key difference: Moody's Corporation is far larger — about 149.7× Tilray Brands Inc's market cap, and Moody's Corporation pays a 0.9% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moody's Corporation for 132 Days and Tilray Brands Inc for 31 Days on average.
| MCO | TLRY | |
|---|---|---|
Market Cap | $79.44B | $530.54M |
Volume | 526,684 | 9,099,075 |
Sector | Financials | Health |
52-Week High | $539.61 | $21.00 |
52-Week Low | $412.23 | $3.57 |
Typical Hold Time | 132 Days | 31 Days |
Enterprise Value | $85.46B | $684.46M |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCO trades at $460.91, up 2.51% today, with a bearish technical signal but strong fundamentals including a 34.25% net income margin and consistent earnings beats. Revenue grew from $5.5B in 2022 to $7.7B in 2025, with a consensus analyst price target of $536.40. Recent news highlights a Zacks upgrade to Buy and a minority stake acquisition in PhilRatings to expand Asia-Pacific presence.
The outlook is positive given robust profitability and growth, but risks include high valuation multiples and technical weakness. Analysts are predominantly bullish, with 56% Buy ratings, suggesting upside potential if earnings momentum continues, though investors should monitor debt levels and market sentiment shifts.
TLRY trades at $3.465, down 6.73% on the day and near 52-week lows, reflecting persistent bearish sentiment. The stock shows weak technical momentum with oversold RSI readings but faces fundamental challenges including consecutive quarterly earnings misses, negative profit margins, and declining revenue growth. Recent news highlights the company's struggles with profitability despite record annual revenue, with shares down over 50% year-to-date as investors question the cannabis company's path to sustainable growth.
TLRY presents a high-risk opportunity with significant downside protection from its low P/B ratio of 0.33, but requires substantial operational improvement to justify investment. The bullish case hinges on potential marijuana reform catalysts and BrewDog integration progress, while risks include ongoing losses, competitive pressures, and execution challenges in a volatile regulatory environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
